[Introduction] The actual controller of Laimei Pharmaceutical may change again China Fund News reporter Lu Wei Following the change of actual controller in 2020, the actual controller of Laimei Pharmaceutical may change again. At present, Laimei Pharmaceutical has been losing mon

[Introduction] The actual controller of Laimei Pharmaceutical may change again

China Fund News reporter Lu Yu

Following the change of the actual controller in 2020, the actual controller of Laimei Pharmaceutical may change again.

Currently, Laimei Pharmaceutical has been losing money for five consecutive years, with a net profit of -26.42 million yuan in the first three quarters of 2024.

The actual controller of Laimei Pharmaceutical may change

Zhongheng Group and Laimei Pharmaceutical simultaneously announced on the evening of November 26 that on November 26, the board of directors of Zhongheng Group reviewed and approved the "Guangxi Wuzhou Zhongheng Group Co., Ltd.’s proposal to transfer the 23.43% shares of Chongqing Laimei Pharmaceutical Co., Ltd. held by the company through a public solicitation of transferees. Zhongheng Group plans to use a public solicitation of transferees. The agreement transfers 23.43% shares of Laimei Pharmaceutical.

After the transfer is completed, Zhongheng Group no longer directly holds Laimei Pharmaceutical shares, but only indirectly holds 2.03% of its shares through Nanning Zhongheng Tongde Pharmaceutical Industry Investment Fund Partnership (hereinafter referred to as Zhongheng Tongde). This matter It may lead to changes in the controlling shareholder and actual controller of Laimei Pharmaceutical.

As of the announcement date, Zhongheng Group directly holds 23.43% of the shares of Laimei Pharmaceutical, and indirectly holds 2.03% of the shares of Laimei Pharmaceutical through its holding subsidiary Zhongheng Tongde; Zhongheng Group directly or indirectly holds a total of 23.43% of the shares of Laimei Pharmaceutical. American Pharmaceuticals holds 25.46% of its shares and is its controlling shareholder.

Zhongheng Group said that in view of the current trend of my country's pharmaceutical policies and the latest development trends of the pharmaceutical market, Zhongheng Group plans to further optimize its business layout at the strategic level and focus on key areas such as cardiovascular and cerebrovascular diseases. In order to optimize the asset structure and improve the operating performance of Zhongheng Group, the company plans to transfer the shares of Laimei Pharmaceutical directly held by the company through public solicitation to improve overall operating efficiency.

Laimei Pharmaceutical has suffered losses for five consecutive years

Laimei Pharmaceutical was established in 1999 and was listed on the GEM of the Shenzhen Stock Exchange on October 30, 2009. It was one of the first 28 companies on the GEM.

Judging from performance, Laimei Pharmaceutical has suffered losses for five consecutive years, with a loss of 26.42 million yuan in the first three quarters of 2024.

On November 26, the share price of Laimei Pharmaceutical closed at 4.85 yuan, with a market value of 5.12 billion yuan; the share price of Zhongheng Group closed at 2.55 yuan, with a market value of 8.76 billion yuan.

Editor: Xiaomo

Review: Muyu